Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
Clinical trial NCT05601830 · TERMINATED
Trial details
- NCT number
- NCT05601830
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-09
- Primary completion
- 2023-06-30
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.